Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Adient heads into its November earnings with short interest rising, options sentiment near a 52-week extreme, and the Street steadily cutting targets on a stock already down 12% in a month.
The sharpest signal this week is in the options market. Traders have rarely been this defensive on Adient: the put/call ratio hit 2.09, near its 52-week high of 2.10, and sits about one standard deviation above its 20-day average of 1.54. What makes that number more striking is its trajectory. The PCR was below 0.70 in early September. It has more than tripled since then, pointing to a rapid build in downside protection among options traders as the stock has sold off through the autumn.
Short interest reinforces the caution, though the borrow market itself remains relaxed. Bears hold 8.8% of the free float short, up 11% over the past month, with the most recent FINRA fortnightly count placing settled short shares at 6.75 million. The build has been steady rather than explosive: positions have risen gradually since late August as the stock slipped from above $22 toward its current $17.51. The lending market, however, tells a different story from the options board. Availability is close to 943% of current short interest, meaning roughly nine shares are available to borrow for every one already lent out. Cost to borrow runs at 0.48%, down around 6% on the week, barely above the risk-free rate. There is no squeeze pressure here. Shorts are comfortable, and new entrants can enter cheaply.
UBS cut its target to $23 from $29 on the day this note was written, maintaining its Buy rating but acknowledging the stock's deterioration. That is the third consecutive reduction by UBS since July, when the same analyst lifted the target to $34. JP Morgan moved in the other direction on the rating in mid-September, upgrading to Overweight from Neutral while cutting its target to $25. Morgan Stanley and Barclays both hold Equal-Weight ratings with targets of $21 and $25 respectively. The consensus mean target of $29 implies substantial upside from current levels, but targets have been moving in one direction: down. The bull case rests on management's stated goal of margin expansion to 5.0% to 5.5% over two to three years and a mid-teens global seating share that could grow through onshoring programs. The bear case is more immediate: loss-making legacy metals contracts, underperforming European plants, and a deteriorating EMEA production mix that continues to drag reported figures. EV/EBITDA at 3.4x and price-to-book at 0.63 make the stock look statistically cheap. The ORTEX factor scores back that up, with EV/EBIT in the 75th percentile. But EPS surprise sits in just the 25th percentile, and the short score rank of 17 flags that the short-selling community is more active here than on most names.
One data point on attention is worth noting. Wikipedia page views for Adient hit a z-score of 2.41 against its own 90-day history as of late September, the highest retail-attention reading in recent months. That kind of spike sometimes coincides with a catalyst or a sharp price move attracting new eyes. The prior quarter's results, reported August 5, produced a 10.9% single-day drop and a 12% decline over the following five days. That reaction set the tone for the current positioning.
Adient's closest peers have fared better this week. LEA gained 2.2% and CPS rose 4.6%, while ALV was essentially flat at up 0.01%. ADNT's 2% weekly gain is modest by comparison but comes off a much lower base after the August earnings rout. With the next results scheduled for November 6, roughly 30 days out, the question is whether the steady short rebuild and the sharp move into puts reflects well-founded execution concern or positioning that has already overshot the fundamental deterioration.
The November 6 print will test whether the Street's revised, more cautious targets are now in line with management's own guidance, and whether the EMEA drag has stabilised or continued to worsen.
See the live data behind this article on ORTEX.
Open ADNT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
